
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is a clinical-stage biotechnology company that is developing novel therapies aimed at enhancing the function of regulatory T cells (Tregs) in diseases with high unmet medical needs, such as neurodegenerative, chronic inflammatory, autoimmune, and metabolic conditions. The company's approach stands out from other therapies in the space as it targets the underlying immune dysregulation and chronic inflammation believed to drive disease progression, rather than just focusing on symptomatic relief or neuronal protection. Recent study data and biomarker findings have supported this approach, and the company's strong financial position allows for continued progress in its clinical pipeline.
Bears say
Coya Therapeutics is facing multiple challenges in the development of their Treg-enhancing therapies. Despite initial promise from biomarker modulation in an investigator-initiated study, there is no direct clinical efficacy update, and the company's COYA 302 drug is still in a randomized trial. Additionally, the company has highlighted various risk factors including regulatory, financial, and commercial risks that could further hinder their progress and success in bringing these therapies to market.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares